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Background
Classical recommended HAART are NRTI+PI or NRTI
+NNRTI combinations. However, some of our HIV
patients have already long durations of NRTI exposure
with confirmed or beginning NRTI toxicities. NNRTI
+PI combinations could be proposed to avoid further
exposure to NRTI.
Methods
We review the data of 19 patients heavely preexposed to
NRTI and submitted to a Lopinavir/r + Efavirenz (Lpv/r
2 × 3 tablets 200 mg/50 mg/d + EFZ 1 × 1 tablet 600
mg/d) combination. Results are expressed as means ±
sem.
Results
Nineteen patients (7 F/12 M; 8 Africans, 1 Asiatic, 11
Caucasians) were submitted to Lpv/r+EFZ during a total
period of 618,5 patient-months (33 ± 5 months). These
patients were 47 ± 2 years old and are regularly followed
for their HIV seropositivity since 123 ± 9 months. Dura-
tion of exposure to any ART before inclusion in this
study was 92 ± 10 m. Three patients discontinued EFZ
rapidly for allergic reactions (2) or psychiatric deteriora-
tion (1), and one discontinued after 16 m due to persis-
tently sleep disturbances. Seven patients discontinued
for hyperlipemia after 30 ± 5 m. Viral loads remained
undetectable (PCR<5 copies RNA/ml) and % CD4 con-
tinued to increase to reach a mean value of 25 ± 2%.
Discussion
The long term follow-up of this small cohort heavely
pre-exposed to NRTI suggests that Lpv/r+EFZ is a
potent antiviral therapy and that further NRTI combina-
tions therapy can be avoided in these patients. The
tolerance to each drug seems not modified by their use
when combined. However, hyperlipemia is a regular
preoccupation.
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